Payer Environment Will Impact Biopharma Prospects In 2017
Executive Summary
An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s JP Morgan Healthcare meeting. Michael Hay, head of Informa Pharma Intelligence Products, shares his thoughts on how shareholder pressure for genuine patient benefits has implications for the pharma and biotech industries.